Semler Scientific

Semler Scientific, Inc. markets products and services for early detection and treatment of chronic diseases. Its FDA-cleared QuantaFlo measures arterial blood flow in the extremities to support early diagnosis of vascular diseases.

Data Systems, Privacy, and Security Officer

Semler Scientific provides medical technology and software enabling point-of-care testing for early chronic disease detection.

Strive finalizes the acquisition of Semler Scientific through an all-stock deal, exchanging each Semler share for 21.05 Strive Class A shares. The merger replaces Semler’s board and officers, prompting the company to request Nasdaq trading suspension and delisting. Semler Scientific will deregister its stock following the transaction.

Jan 2026Investing.comNews article

Strive is acquiring Semler Scientific in an all-stock deal, offering a **210% premium** per share. The transaction includes **5,816 Bitcoin** purchased for **$675 million**, expanding Strive’s total Bitcoin holdings to nearly **10,900 BTC**. The combined entity aims to leverage Semler’s assets while bolstering its cryptocurrency reserves.

Sep 2025Yahoo FinanceNews article

Semler Scientific pays **$30 million** to the U.S. Department of Justice to resolve fraud allegations linked to its **QuantaFlo** medical devices. The company also announces that **UnitedHealth**, which represented nearly half of its **Q2 2025 revenue**, will discontinue using the product starting **October 2025**. The settlement follows investigations into billing practices tied to the devices’ use.

Sep 2025STATNews article

Semler Scientific shifts focus to bitcoin ventures as federal scrutiny intensifies over its QuantaFlo artery test, which has faced Medicare Advantage insurer pushback, including from UnitedHealth. The pivot follows a STAT investigation into the company’s reliance on Medicare Advantage sales. Regulatory pressure appears to drive the strategic change away from its core medical device business.

Jun 2025STATNews article